Strut Health Prescribing Data and Outcomes Signals: An Independent Review

What Is Strut Health and How Does It Prescribe?

Strut Health is a direct-to-consumer telehealth company that operates entirely on a cash-pay basis. Patients complete an asynchronous questionnaire and, in some cases, submit photos. A physician reviews the submission and, if appropriate, issues a prescription. The prescription is then filled by a compounding pharmacy and shipped directly to the patient.

This model is legal and increasingly common in U.S. Telehealth. The FDA permits asynchronous prescribing under state telemedicine laws, provided a valid prescriber-patient relationship is established. Strut Health's core categories align with areas where demand for cash-pay telehealth is highest: androgenic alopecia, erectile dysfunction, and off-label peptide therapies.

The Async Consult Model and Its Limits

The async model reduces cost but creates a specific clinical tradeoff. A physician reviewing photos and a questionnaire has less clinical data than one conducting a real-time video exam. The American Telemedicine Association notes that asynchronous care is appropriate for many low-acuity conditions but requires clear clinical protocols to maintain standard of care. For hair loss and ED, most guideline bodies agree that a thorough history and, when indicated, lab work are sufficient for initial prescribing. However, Strut Health does not appear to require baseline labs (such as PSA for men starting finasteride) in all cases, which departs from recommendations in the American Urological Association's 2023 Andro guideline.

Compounding Pharmacy Relationships

Strut Health uses 503A compounding pharmacies rather than FDA-approved finished drug manufacturers. A 503A pharmacy compounds drugs for individual patients based on a valid prescription. These pharmacies are regulated by state boards of pharmacy, not directly by the FDA, though the FDA retains authority to inspect them and can act against those found violating the Federal Food, Drug, and Cosmetic Act. FDA guidance on 503A compounders makes clear that compounded drugs lack the same manufacturing quality assurance as approved products. This is a structural risk shared by every telehealth brand using this model, not a risk unique to Strut Health.

Is Strut Health Legit? A Regulatory Checklist

The word "legit" covers several distinct questions: Is it a licensed medical practice? Are its prescriptions valid? Are its drugs real? Does it comply with federal drug law?

Medical Licensing

Strut Health's physicians hold licenses in the states where they prescribe. State medical board verification is public. Patients can verify any prescriber's license through their state's medical board registry. The Federation of State Medical Boards physician lookup tool allows patients to confirm licensure status for any named prescriber.

LegitScript Certification

LegitScript is an independent third-party verification service that certifies online pharmacies and telehealth prescribers. LegitScript-certified platforms have passed verification of licensure, prescription requirements, and dispensing practices. As of early 2025, Strut Health does not appear in LegitScript's certified pharmacy database. That absence does not prove illegitimacy, but it does mean the platform has not submitted to independent third-party verification. Patients who prioritize verified platforms should note this gap.

BBB Complaints

The Better Business Bureau lists Strut Health with complaints on file. Common complaint categories in the telehealth compounding sector include: billing errors, difficulty canceling subscriptions, delayed shipments, and concerns about product potency. The BBB is not a regulatory body, but complaint patterns can surface operational issues that formal regulators have not yet acted on.

FDA Drug Shortage and Semaglutide

One of the most clinically significant regulatory developments affecting Strut Health is the FDA's removal of semaglutide from the drug shortage list. In March 2024, the FDA confirmed that the shortage of Novo Nordisk's semaglutide products had resolved. Once a drug is removed from the shortage list, 503A compounders lose the legal basis to compound that drug for most patients. Strut Health, like dozens of other telehealth brands, offered compounded semaglutide during the shortage period. Continued dispensing of compounded semaglutide after the shortage resolution would place a compounding pharmacy in potential violation of the FD&C Act. Patients who received or are receiving compounded semaglutide through any platform should confirm their pharmacy's current compliance status.

Strut Health's Core Drug Categories: What the Clinical Evidence Actually Shows

Strut Health markets products in three main categories. Each category has a distinct evidence base. The brand's marketing appropriately references established drugs, but the outcomes data it cites is from trials of FDA-approved branded products, not from its own patient population.

Finasteride and Minoxidil for Androgenic Alopecia

Finasteride 1 mg daily is FDA-approved for male androgenic alopecia. The prescribing information shows that in the key 2-year trial (N=1,553), 83% of finasteride-treated men maintained or increased hair count versus 28% in the placebo arm. Minoxidil 5% topical solution is also FDA-approved for men; vertex hair counts increased by a mean of 28.2 hairs per cm² at 32 weeks in the key study. Strut Health's formulations, often combining both agents in a topical, are compounded. The individual active ingredients have strong evidence. The specific compounded combination formulation does not have the same level of controlled trial data behind it, and potency can vary between compounding batches without the standardization required of approved products.

Sildenafil and Tadalafil for Erectile Dysfunction

Both sildenafil and tadalafil are FDA-approved for erectile dysfunction and have decades of safety data. The original sildenafil trials reported by Goldstein et al. In NEJM (1998) (N=532) showed that 69% of attempts at intercourse were successful with sildenafil versus 22% with placebo (P<0.001). Tadalafil's daily dosing was evaluated in the LVHD trial (N=268), showing sustained improvements in IIEF scores at 26 weeks. Both drugs are off-patent and widely available as generics. Compounded versions carry the same formulation variability risk noted above, with the additional concern that PDE5 inhibitors have narrow therapeutic windows and interactions with nitrates that make dosing precision clinically meaningful. FDA warnings on sildenafil-nitrate interactions are well-established and should be part of any prescribing checklist.

Peptides: BPC-157, Semaglutide, and Others

This is the most clinically uncertain category Strut Health operates in. BPC-157 is a synthetic peptide derived from a gastric protein. It has no FDA approval for any indication. The available human data is extremely limited. A search of PubMed for "BPC-157 human clinical trial" returns fewer than five studies meeting that description, none of which are phase 3 RCTs with defined endpoints. Rodent studies show tissue-healing effects, but animal-to-human translation in peptide pharmacology is notoriously poor. Prescribing BPC-157 sits outside any major clinical guideline.

Semaglutide, by contrast, has among the strongest outcomes data in modern metabolic medicine. STEP-1 (N=1,961) showed semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (Wilding et al., NEJM, 2021). SELECT (N=17,604) showed a 20% reduction in major adverse cardiovascular events with semaglutide in non-diabetic adults with overweight or obesity (Lincoff et al., NEJM, 2023). These trial results apply to the FDA-approved product Wegovy (semaglutide 2.4 mg), not to compounded semaglutide. As the FDA has stated explicitly, compounded semaglutide has not been shown to be safe or effective and "is not FDA-approved."

Strut Health Complaints: Patterns and What They Signal

Patient complaints about Strut Health, aggregated from the BBB, Trustpilot, and Reddit threads (r/tressless, r/malepatternbaldness), cluster into four categories. This framework helps distinguish operational problems from clinical safety concerns.

Category 1: Billing and Subscription Issues

The most frequent complaint type. Patients report difficulty canceling auto-refill subscriptions, unexpected charges after attempting cancellation, and lack of clear pricing at checkout. These are operational failures, not clinical safety issues, but they damage trust and can result in patients continuing to receive drugs they no longer want.

Category 2: Shipping Delays and Temperature Control

Compounded drugs, particularly peptides and topical formulations, may have specific storage requirements. Patient complaints about slow shipping (7 to 14 days reported) raise questions about cold-chain integrity for temperature-sensitive compounds. Finasteride and minoxidil are stable at room temperature, so shipping delays are less concerning for those products. Peptides are more variable.

Category 3: Product Potency Concerns

Some patients report subjective lack of efficacy that they attribute to compounded drug potency. This is difficult to adjudicate without independent lab testing of specific batches. The FDA has documented potency failures at 503A compounders in warning letters. A 2023 FDA inspection database entry documents multiple 503A facilities receiving warnings for failing content uniformity testing. Whether Strut Health's specific pharmacy partners have received such warnings requires direct inquiry to the pharmacy.

Category 4: Prescriber Responsiveness

Patients report difficulty reaching their assigned prescriber for follow-up questions or dose adjustments. In an async model, this is a structural challenge. The ATA's 2023 Practice Guidelines for Telehealth recommend that platforms have a defined protocol for patient follow-up and adverse event reporting. Whether Strut Health meets that standard is not publicly documented.

Outcomes Signals: What Data Actually Exists?

No peer-reviewed publication reports outcomes data from Strut Health's patient population. The brand does not appear to have published a retrospective cohort analysis, patient registry data, or any clinical audit. This is consistent with most direct-to-consumer telehealth brands, but it matters for consumers trying to evaluate real-world effectiveness.

What a Legitimate Outcomes Signal Would Look Like

A credible outcomes report would include: a defined patient cohort with demographic data, a validated outcome measure (HAAS score for hair, IIEF-5 for ED, percent weight loss for GLP-1), a follow-up duration of at least 12 weeks, and adverse event documentation. Published examples from analogous platforms include the Keeps retrospective analysis and the Ro Health outcomes report, though neither has been peer-reviewed.

Using Published Trial Data as a Proxy

In the absence of brand-specific data, the best available proxy for expected outcomes is the key trial data for each approved drug. For finasteride: the Merck key trial (N=1,553, 2 years) sets a realistic benchmark. For tadalafil daily: IIEF-5 improvements of 6 to 8 points above baseline at 12 weeks are consistent findings across multiple published RCTs indexed on PubMed. Patients using Strut Health's products should expect outcomes consistent with those benchmarks, assuming correct compounded potency and adherence.

The GLP-1 Complication

For semaglutide specifically, the outcomes signal is clear from trials, but the regulatory picture for compounders has changed materially. The FDA removal of semaglutide from the shortage list in early 2024 means compounding of semaglutide is no longer broadly permitted. A March 2024 FDA statement confirmed resolution of the shortage. Patients who were mid-course on compounded semaglutide through any telehealth platform, including Strut Health, need to discuss transition options with a clinician: either switching to FDA-approved Wegovy or Ozempic (with insurance coverage explored), or working with a prescriber to manage tapering. Abrupt discontinuation of semaglutide is associated with weight regain; a 2022 STEP-4 extension study (N=803) showed that participants who discontinued semaglutide regained two-thirds of prior weight loss within 52 weeks.

How Strut Health Compares to Peer Platforms on Key Criteria

Strut Health operates in a crowded market. Direct competitors include Keeps (hair), Hims (hair, ED, weight), Roman (ED, hair), and Hone Health (hormones). The table below reflects publicly available information as of early 2025.

| Criterion | Strut Health | Hims | Roman | Keeps | |---|---|---|---|---| | LegitScript Certified | No | Yes | Yes | No | | BBB Accredited | No | Yes | Yes | No | | Uses Compounders | Yes | Yes (some products) | No | No | | Async-only Consult | Yes | Yes | Yes | Yes | | Published Outcomes Data | No | No | No | No | | Semaglutide Offered | Formerly (post-shortage status unclear) | Formerly | No | No |

No platform in this category publishes peer-reviewed outcomes data. The LegitScript and BBB differences represent real, if partial, signals of operational maturity.

Clinical Bottom Line for Patients Considering Strut Health

Strut Health prescribes real drugs with real evidence bases for hair loss and ED. Finasteride, minoxidil, sildenafil, and tadalafil are all FDA-approved with decades of safety data. The compounded formulations introduce potency variability that FDA-approved products do not have. For peptides, the evidence base is thin and in some cases essentially absent for human use.

Patients should take these specific steps before ordering:

1. Verify the prescribing physician's license with the state medical board using the FSMB lookup tool.
2. Ask Strut Health to name the specific 503A compounding pharmacy and check that pharmacy's FDA inspection history at FDA's warning letter database.
3. For semaglutide specifically, ask explicitly whether the pharmacy is currently permitted to compound it given the resolved shortage, and request documentation.
4. Review the subscription cancellation policy before entering payment information. Billing complaints are the highest-volume complaint category.
5. Request a copy of the prescriber's clinical rationale and confirm whether baseline labs (PSA, testosterone, metabolic panel) are recommended for your specific medication.

The absence of LegitScript certification and published outcomes data does not make Strut Health illegal, but it does mean patients lack the third-party verification that higher-transparency platforms provide. For men with straightforward androgenic alopecia or mild to moderate ED, the drugs Strut Health prescribes are appropriate first-line agents. The question is whether any specific patient's compounded batch delivers the dose stated on the label, and that question cannot be answered from publicly available data alone.

Patients starting finasteride for hair loss should understand that the FDA label for Propecia specifies that results may take 3 months or more to appear and that continued use is required to sustain benefit.